Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4434MR)

This product GTTS-WQ4434MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4434MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14880MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ13744MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ2933MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ13911MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ4146MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754091
GTTS-WQ6888MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ16012MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ5807MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CFZ-533
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW